Related references
Note: Only part of the references are listed.Should Oncologists Be Aware in Their Clinical Practice of KRAS Molecular Analysis?
Daniele Santini et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue
Jolien Tol et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
KRAS mutation testing in patients with metastatic colorectal carcinoma: An 18-month experience emphasizing the risk of false-negative results
F. Bibeau et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
Marc Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach
Pietro Carotenuto et al.
PHARMACOGENOMICS (2010)
Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer
Pierre Laurent-Puig et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Targeted KRAS Mutation Assessment on Patient Tumor Histologic Material in Real Time Diagnostics
Vassiliki Kotoula et al.
PLOS ONE (2009)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: A reliable predictor for patient outcome
Tsung-Teh Wu et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
Sensitive Sequencing method for KRAS mutation detection by pyrosequencing
S Ogino et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2005)
Share Paper
